Consonance Capital Partners Completes Recapitalization of Orsini Pharmaceutical Services in Partnership with Management Team

NEW YORK & ELK GROVE VILLAGE, Ill.–(BUSINESS WIRE)–Consonance Capital Partners, a leading healthcare-focused private equity
fund, announced today that it completed the recapitalization of Orsini
Pharmaceutical Services, LLC, (“Orsini” or the “Company”) in partnership
with the Company’s CEO and President, Michael Fieri. Orsini is a leading
rare disease specialty pharmacy differentiated by its personalized
service and focus on complex conditions that require a high-touch
patient journey. Financial terms of the transaction were not disclosed.

Orsini’s mission is to improve the quality of life for patients living
with difficult conditions,” commented Michael Fieri. “We partnered with
Consonance not only because of their similar commitment to improving
patient care but also as a result of their sector knowledge, extensive
relationships, national reach, and their decades of healthcare investing
experience more broadly. I am confident the additional resources this
partnership brings will help us further expand our services and support
our growth.”

Consonance has long viewed specialty pharmacy as a sector uniquely
positioned to improve outcomes through increased adherence and
high-touch care coordination,” noted Stephen McKenna, Managing Partner &
Co-Founder of Consonance Capital Partners. “Orsini is an exemplary model
of how an innovative patient-centric approach and consistent culture of
care can improve quality and lead to a strong value proposition for
patients, manufacturers, and payors. We are excited to partner with Mike
Fieri and the team to further expand their proven model of patient care
targeting those who need it most.”

Javier Starkand, a Principal of Consonance Capital Partners, added, “At
Consonance, we pride ourselves on investing in companies that improve
lives and patient care, which is the reason we are excited to join Mike
and the rest of the Orsini team. We have been thoroughly impressed with
Orsini’s highly personalized approach to care and its reputation for
innovation, data collection capabilities, and domain expertise in rare
diseases, and we look forward to working with them as they continue to
improve care for patients.”

Consonance Capital Partners was advised by Latham & Watkins LLP and
Bass, Berry & Sims PLC. Orsini Pharmaceutical Services was advised by
Barone Law Group P.C., Levenfeld Pearlstein, LLC, and Brown & Fortunato,
P.C.

About Consonance Capital Partners

Consonance Capital Partners invests in private companies in the lower
middle market of the U.S. healthcare industry with an emphasis on
businesses driving efficiency, cost containment and high quality
clinical care to patients. Consonance Capital Partners participates in
growth equity, leveraged buyout, and recapitalization transactions. For
more information, visit www.consonancecapital.com.

About Orsini Pharmaceutical Services

Orsini is a leading independent national specialty pharmacy focused on
patients with rare and complicated diseases. Orsini’s services allow
patients, physicians, payers and manufacturers to improve care, simplify
processes and achieve better outcomes. The Company’s comprehensive
solutions include nursing coverage nationwide for required in-home
infusion services, data analytics, and medication adherence, among
others. The Company distributes its products nationally under limited
and exclusive distribution contracts with manufacturers. Based in Elk
Grove Village, IL, Orsini has been accredited by URAC, VIPPS, ACHC, and
JCAHO. For more information, visit www.orsinihealthcare.com.

Contacts

Media
Sloane & Company
Whit Clay, 212-486-9500
wclay@sloanepr.com

error: Content is protected !!